Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• DLX2 marks an immunosuppressive dendritic-cell program that reshapes cytotoxic immunity and marks a tolerogenic microenvironment in lung adenocarcinoma.

  PMID 41761000 · PMC13043845 · Discover oncology · 2026 · 8 claims · 8 setups

  Full-text index only

  Neuroactive ligand–receptor signaling is among the most significantly upregulated pathways in LUAD relative to normal lung tissue.

  tcga-luad tcga luad dendritic-cell bulk survival pan-cancer

• Multimodal profiling of pancreatic cancer reveals a TIMP-1-dominated secretory profile determining pro-tumor immunoinstruction in human cancers.

  PMID 41564862 · PMC12866174 · Cell reports. Medicine · 2026 · 8 claims · 8 setups

  Full-text index only

  A 19-factor cancer-immunoinstructive secretory signature (CISS) is present across multiple human cancers and correlates with pro-tumorigenic tumor microenvironments and poor patient survival.

  pancreatic kpc pdac tcga-paad rna-seq bulk proteomics

• Helicobacter pylori-linked gene CFAP73 rewires epithelial programs and shapes the gastric cancer microenvironment.

  PMID 41934579 · PMC13199538 · Discover oncology · 2026 · 8 claims · 8 setups

  Full-text index only

  CFAP73 is progressively downregulated during HP infection and is the top-ranked predictor among nine HP-suppressed genes associated with favorable gastric cancer survival

  gastric tcga-stad tcga t-cell–tumor jonckheere-terpstra survival random

• IMIREG: a lineage-resolved regulon signature unveiling immune engagement archetypes and predicting immunotherapy response across diverse cancers.

  PMID 42092126 · PMC13234301 · NPJ precision oncology · 2026 · 8 claims · 8 setups

  Full-text index only

  IMIREG, a 14-regulon transcriptional signature, robustly predicts clinical benefit from ICB across 50 immunotherapy cohorts (52 treatment arms) spanning 16 cancer types with mean AUROC = 0.71

  imvigor210 matched gtex healthy bulk scrna-seq pathway